Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent inactivated COVID-19 vaccine (PUC)
- Development stage
- Unknown
- Lead developer
- Pontificia Universidad Católica de Chile
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The trivalent inactivated COVID-19 vaccine developed by the Pontificia Universidad Catolica de Chile (PUC) is an experimental whole-virus vaccine designed to provide broad protection against multiple variants of SARS-CoV-2. It incorporates inactivated viral particles from three distinct lineages: the ancestral strain (CZ02), the Delta variant, and the Omicron variant. The vaccine is produced by growing the viruses in Vero cells, followed by inactivation and formulation with aluminum hydroxide as an adjuvant. It is primarily being evaluated in clinical trials as a booster dose for adults who have previously completed a primary vaccination schedule, with the aim of eliciting superior immunogenicity against circulating variants of concern compared to monovalent ancestral vaccines like CoronaVac.
- Other names
- Trivalent VaccineCoronaVarCL trivalent vaccinetrivalent vaccine-Pontificia Universidad Catolica de Chile-COVID-19
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)M protein (SARS-CoV-2 membrane protein)E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on trivalent inactivated COVID-19 vaccine (PUC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent inactivated COVID-19 vaccine (PUC).